NAD+ Research: Mechanism, Human Trials, and Injectable Pharmacokinetics

Before the details

NAD+ (the cell's energy-handling helper molecule) does two jobs. First, it carries electrons during the chemistry that turns food into ATP (the cell's energy currency) — flipping between an "empty" form (NAD+) and a "loaded" form (NADH). Second, it is used up as fuel by repair-and-maintenance enzymes. This page reads the studies behind both jobs, then the human trials of oral precursors (NMN, NR), then what the few pharmacokinetic studies of NAD+ injections and IV drips actually found. Doses appear only as what was given to whom in a study — never as advice.

Mechanism: a redox carrier and a consumed signal

NAD+ cycles between its oxidized form (NAD+) and reduced form (NADH) to shuttle electrons through glycolysis, the TCA cycle, and the mitochondrial electron transport chain, driving oxidative phosphorylation and ATP synthesis ^[5]. That is its housekeeping role, and it is continuous. Its second role is regulatory and destructive of the molecule: sirtuins (SIRT1-7) consume NAD+ to deacylate target proteins, PARP1 consumes large amounts during DNA repair, and CD38/CD157 hydrolyze it as ectoenzymes ^[5]. Because these consumers draw on the same pool, NAD+ links energy metabolism to DNA repair, gene regulation, and inflammation in one currency ^[5].

The rate-limiting step of resupply is NAMPT, the salvage enzyme that recycles nicotinamide back toward NAD+ ^[5]. NAMPT activity is not static — it follows a circadian rhythm and is induced by exercise — which is part of why NAD+ is described as a dynamic, demand-sensitive pool rather than a fixed reserve ^[5]. A mouse model makes the demand side vivid: in ANT1-deficient mice, exercise created an NAD+ shortfall that stalled the TCA cycle and muscle respiration, and nicotinamide riboside raised muscle and liver NAD+ and improved exercise capacity ^[12].

Nicotinamide Riboside (NR): The Most-Studied Oral Precursor

Nicotinamide riboside is the most clinically studied oral NAD+ booster, and its human pharmacodynamics are well characterized. In a randomized, double-blind, placebo-controlled trial of healthy overweight adults, NR at 100, 300, and 1000 mg/day for eight weeks raised whole-blood NAD+ by 22%, 51%, and 142% respectively, with the elevation maintained throughout the study ^[4]. NR did not cause flushing, did not raise LDL cholesterol, and did not disrupt one-carbon metabolism at any dose ^[4]. Beyond pharmacodynamics, NR's preclinical record includes reduced diet-induced weight gain and liver fat in rodents ^[6] and improved respiration in a mitochondrial myopathy model ^[12]. NR's strength is the clean, dose-scalable, well-tolerated rise in blood NAD+; its human outcome data beyond that biomarker remain more limited ^[13].

Nicotinamide Mononucleotide (NMN): A Direct NAD+ Precursor

Nicotinamide mononucleotide sits one step from NAD+ and carries the strongest human outcome signals in this record. A multicenter, double-blind, placebo-controlled, dose-dependent trial gave 300, 600, or 900 mg/day for 60 days to healthy middle-aged adults; blood NAD+ rose significantly at days 30 and 60 across all groups (p ≤ 0.001), six-minute walking distance improved, a biological-age measure did not increase, and 600 mg/day was identified as optimal with no safety issue at any dose ^[3]. In prediabetic postmenopausal women, 250 mg/day for 10 weeks increased muscle insulin sensitivity ^[1]. NMN's animal record is deep in aging biology — restored oocyte NAD+ and ovarian reserve markers in aged mice ^[9][10] and improved metabolic measures in rodent models ^[6].

One caveat is regulatory rather than scientific. The FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug, creating an unsettled marketplace dispute over how NMN may be sold ^[13]. That is a commercial and legal question — not a finding that NMN is unsafe and not a statement that NMN is "banned."

Injectable and IV NAD+: What the Pharmacokinetic Studies Show

Injectable and IV NAD+ — the route that delivers NAD+ rather than a precursor — has the weakest controlled evidence of any approach. A NAD injection or infusion is a compounded preparation; it is not FDA-approved. The pharmacokinetic reality is the headline finding: infused NAD+ is extensively metabolized extracellularly and rapidly cleared from plasma, with a pilot study reporting near-complete plasma removal within roughly the first two hours of infusion ^[13]. In other words, much of what is infused is broken down before cells take it up as NAD+.

A cold-amber caution belongs here. Compounded injectable NAD+ carries documented quality risk: the FDA has issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin ^[13]. Reconstituted injectable NAD+ is also unstable, requiring cold, light-protected storage ^[6]. None of this establishes IV NAD+ as an approved or proven therapy; it is an unapproved compounded wellness preparation with a thin evidence base and a real contamination precedent. See doses used in the research for the reported infusion protocols, stated as reported, not recommended.

IV NAD+ Therapy in Pilot and Retrospective Studies

What controlled-ish evidence exists for IV NAD+ therapy is pilot or retrospective, not randomized. The pharmacokinetic pilot above documented extensive extracellular metabolism and rapid plasma clearance of infused NAD+ ^[13]. Tolerability is the other recurring theme: infusions run too fast can cause chest and abdominal discomfort, flushing, and nausea ^[13]. Across this record, the IV route raises NAD+ transiently at best and has not been shown to improve any clinical endpoint in a controlled human trial ^[13]. This site reports those findings; it does not endorse the therapy.

Beyond aging: kidney and metabolic models

NAD+ research extends past longevity into organ-protection models, almost entirely preclinical. In mouse acute kidney injury, NAD+ precursor supplementation prevented cisplatin- and ischemia-reperfusion-induced damage by suppressing mitochondrial-RNA/RIG-I inflammatory signaling, lowering creatinine and injury markers such as NGAL and KIM-1, with NMN and NR showing similar efficacy ^[7]. In metabolic models, NMN and NR improved insulin sensitivity, glucose tolerance, and hepatic lipid accumulation ^[6]. These are mechanism-rich rodent results that motivate human study; they are not evidence that NAD+ or its precursors treat kidney or metabolic disease in people ^[13].